Showing 141 - 160 results of 31,390 for search '(((( ((c large) OR (b large)) decrease ) OR ( a large decrease ))) OR ( 3 cases increased ))', query time: 1.63s Refine Results
  1. 141
  2. 142
  3. 143
  4. 144
  5. 145
  6. 146
  7. 147
  8. 148
  9. 149
  10. 150
  11. 151

    Table4_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  12. 152

    Table3_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  13. 153

    Table6_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  14. 154

    Table1_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.DOCX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  15. 155

    Table2_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  16. 156

    Table5_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  17. 157
  18. 158

    Table 1_Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target.docx by Lili Zhou (265076)

    Published 2025
    “…</p>Methods<p>We retrospectively analyzed clinical data from 200 DLBCL patients and 185 healthy controls, focusing on lipid and lipoprotein levels, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and apolipoprotein E (ApoE). …”
  19. 159

    Data Sheet 1_Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target.docx by Lili Zhou (265076)

    Published 2025
    “…</p>Methods<p>We retrospectively analyzed clinical data from 200 DLBCL patients and 185 healthy controls, focusing on lipid and lipoprotein levels, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and apolipoprotein E (ApoE). …”
  20. 160